Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-07-05 pm EDT 5-day change 1st Jan Change
7.005 USD -8.79% Intraday chart for Kyverna Therapeutics, Inc. -6.60% 0.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HC Wainwright Initiates Kyverna Therapeutics at Neutral With $8 Price Target MT
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Small Cap Comp Value Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Small Cap Completeness Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 2000 Value Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Microcap Growth Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 3000 Value Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 2000 Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 3000E Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 2500 Value Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Microcap Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 2500 Growth Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Small Cap Comp Growth Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 3000E Growth Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 3000 Growth Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 2000 Growth Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 2000 Dynamic Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Microcap Value Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 3000E Value Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 2500 Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell 3000 Index CI
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to S&P Global BMI Index CI
Sector Update: Health Care Stocks Higher Late Afternoon MT
Kyverna Therapeutics Gets FDA Investigational New Drug Application Clearance for KYV-101 to Treat Stiff-Person Syndrome MT
Kyverna Therapeutics Shares Rise 13% After FDA Clearance for KYV-101 DJ
Kyverna Therapeutics Gets FDA IND Clearance for KYV-101 DJ
Chart Kyverna Therapeutics, Inc.
More charts
Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. It is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.005 USD
Average target price
35.8 USD
Spread / Average Target
+411.06%
Consensus
  1. Stock Market
  2. Equities
  3. KYTX Stock
  4. News Kyverna Therapeutics, Inc.
  5. Kyverna Therapeutics Shares Fall After Early Data on CAR T Cell Therapy Candidate